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Abstract Nuclear factor KB (NF-KB) is a transcription factor 
that is critical for the inducible expression of multiple cellular 
and viral genes. Using the electrophoretic mobility shift assay, we 
demonstrated that DNA binding activity of NF-KB was abolished 
by proteolysis with p- and m-calpains in vitro. The proteolysis of 
NF-KB by calpains and hence the abolition of its DNA binding 
was prevented by calpastatin, calpain inhibitor I and proteasome 
inhibitor. We also provided evidence that calpains degrade the C- 
terminal domain of NF-KB by Western blot using anti-NF-KB 
(~65) C-terminal antibody. These observations indicate that 
calpains regulate gene expression through processing of NF-KB. 
Key wor&: Nuclear factor KB; DNA binding; EMSA; 
Calpain; Protease inhibitor; Western blot; Gene expression 
1. Introduction 
Calpains (EC 3.4.22.17) are intracellular calcium-dependent 
cysteine proteases ubiquitously distributed in animal tissues 
[ 1,2]. There are at least two types of calpains, l.t- and m-cal- 
pains, which require a micromolar and a millimolar concen- 
tration of Ca2+ for activation, respectively. Enzyme activity is 
physiologically regulated by an endogenous calpain specific 
inhibitor, calpastatin [1,2]. Presence of both types of calpains 
in mammalian tissues and cells was demonstrated by measure- 
ment of proteolytic activity [3], immunological detection [4-61, 
and molecular cloning [7-91. Both calpains have distinct large 
catalytic subunits and an identical small regulatory subunit 
[lo]. Calpains hydrolyze various endogenous proteins 
[ 11,121, calmodulin binding proteins [ 13,141 and components 
of receptor signaling pathways [ 15,161. Additionally, various 
transcription factors, including API (c-Fos/c-Jun), AP 2, Pit- 
1, Ott-1, CP la and b, c-Myc, ATFKREB and AP 3, were 
cleaved by m-calpain to produce specific partial digestion 
products [ 17,181. These properties of calpains raise the possi- 
bility that they are involved in regulation of turnover of tran- 
scription factors in vivo. 
Nuclear factor KB (NF-KB) is one of the transcription fac- 
tors and regulates a wide variety of cellular and viral genes 
including several cytokines, cell adhesion molecules, inducible 
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NO synthase, and human immunodeficiency virus (HIV) 
[19,20]. Although NF-KB is by no means the sole determinant 
of inducible expression of these genes, it has been shown to 
play a significant role [20]. Previous studies demonstrated that 
NF-KB binding to the specific DNA sequence (called KB mo- 
tif) is essential for the transcriptional activity. The induction 
of cell function by NF-KB is independent of new protein 
synthesis and involves dissociation and translocation of NF- 
KB to the nucleus where it activates the target genes [19]. 
However, the regulating pathway of protein turnover of 
NF-KB is largely unknown. In this study we investigated 
whether calpain is involved in turnover of NF-K-B. 
2. Materials and methods 
2.1. Reagents 
DEAE-Sephacel, heparin-Sepharose CL-6B and poly(dI-dC) were 
purchased from Pharmacia (Uppsala, Sweden). Calpain inhibitor I 
(N-acetyl-leucyl-leucyl-norleucinal) was supplied by Nakarai (Kyoto, 
Japan). Proteasome inhibitor (carbobenzoxy-L-leucyl-L-leucyl-norval- 
inal) was supplied by Peptide Institute, Inc., Japan and calpastatin 
domain I was the product of Takara Shuzo Co., Ltd. (Otsu, Japan) 
[21]. Western blot was performed with the affinity-purified rabbit 
polyclonal antibody against the C-terminal peptide of the NF-KB 
p65 subunit [22] using a Mini-Protean II slab gel SDS-PAGE system 
and immunoblot kit (BioRad, Hercules, CA). 
2.2. Preparation of NF-KB and calpain 
p-Calpain was purified from human red blood cells and m-calpain 
was from human placenta as described previously [23,24]. NF-KB was 
prepared from the nuclei of human lymphocyte as reported previously 
[25,26]. Briefly, the crude nuclear extract was prepared by the method 
of Dignam et al. [27] and was fractionated on heparin-Sepharose and 
DEAE-Sephacel column [28,29]. NF-wB was eluted from the DEAE- 
Sephacel column by a buffer containing 0.3 M KCl. The fractions 
containing NF-rB were pooled, dialyzed against the DNA binding 
buffer and concentrated using Centricon 30 (Amicon, Beverly. MA). 
2.3. Digestion of NF-KB by calpain 
NF-KB solution (2 ~1) was premixed with a 1 ~1 aliquot of a calpain 
solution (%5 pg/ml) diluted to various protein concentrations with 
buffer containing 20 mM HEPES, 20% glycerol, 60 mM KCI, 0.5 
mM PMSF and 0.2 mM EDTA, pH 7.9. The reaction was started 
by adding 1 ~1 of CaClz (final concentration of 1 mM in a typical 
experiment) at 30°C. After incubation, EGTA was added at a final 
concentration of 3 mM to terminate the enzyme reaction before add- 
ing the radiolabeled DNA probe for EMSA. 
2.4. Eiectrophoretic mobility shift assay (EMSA) 
The DNA binding activity of NF-KB was examined by EMSA using 
a-32P labeled double-stranded KB oligonucleotide as a probe 
[25,26,28]. The NF-KB binding sequence, KB sequence, was iaken 
from human immunodeficiencv virus type 1 (HIV-I) 1261. The se- 
quences (plus strand) of the w-ild-type and muiant-type’& oligonu- 
cleotides are as follows: 
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wild type KB 5’ TTTCTAWACTTTCCGCCTGGGGACTT- 
TCCAG 3’ 
mutant KB 5’ TTTCTAmACTTTCCGCCTGCTCACTT- 
TCCAG 3’. 
Three thymidine residues were added to each oligonucleotide se- 
quence by end-labeling with klenow DNA polymerase (Takara Shuzo 
Co., Ltd., Otsu, Japan) and [@P]dATP (3000 Ci/mmol, ICN Bio- 
medicals, Inc., Costa Mesa, CA). Binding reactions of the DNA probe 
with protein were performed at 30°C for 10 min in a total volume of 
10 11 of buffer containing 22 mM HEPES-KOH (pH 7.9), 60 mM 
KCl, 0.2 mM EDTA, 5% (v/v) glycerol, 0.1% Nonidet P-40, 1 mM 
dithiothreitol (DTT), 1.0 pg poly(dI-dC), 1.0 pg tRNA and 0.1 ng 
(20000-30000 cpm) of the labeled ‘KB’ DNA probe. The labeled 
DNA probe was purified by passing through a gel filtration column 
(Quick Spin Column Sephadex G-25, Boehringer, Mannheim, Ger- 
many) according to the instructions provided by the manufacturer. 
After electrophoresis, gels were dried under vacuum and autoradio- 
graphed with Kodak T-Mat films (Eastman Kodak Co., Rochester, 
NY) at -80°C. 
2.5. Western blot analysis 
To confirm the digestion of NF-KB by calpains, Western blot anal- 
ysis was performed using specific polyclonal antibody to the C-term- 
inal peptide of the ~65 subunit of NF-KB [26]. NF-KB was incubated 
with various concentrations of p-calpain and m-calpain in the pre- 
sence of a final concentration of 1 mM Ca2+ at 3O’C for 30 min 
before running on a 5-20% gradient SDS-PAGE gel and was elec- 
tro-transferred at 4°C to polyvinylidene difluoride (PVDF) membrane 
in a buffer containing 20 mM Tris-glycine (pH 8.2) and 10% metha- 
nol. After washing with Tris-HCl (pH 7.4) buffer, the membrane was 
blocked with 1% casein in PBS for 8 h at 4”C, and subsequently 
incubated with 5 pg protein per ml of the affinity purified anti-NF- 
KB (~65) C-terminal antibody for 3 h at 30°C. After washing, the 
membrane was incubated with alkaline phosphatase conjugated anti- 
rabbit IgG antibody (1:3000) (Bio-Rad) for 3 h at 30°C and 5-bromo- 
4-chloro-3-indoyl phosphate/nitroblue tetrazolium as substrate. 
3. Results 
3.1. Preparation and ident$cation of NF-KB 
NF-KB was partially purified from the nuclei of human 
lymphocytes as described in section 2. The DNA binding ac- 
tivity of NF-KB was measured by EMSA using the radiola- 
beled KB DNA probe. The specificity of NF-KB DNA binding 
activity was confirmed by DNA competition experiments by 
adding 50-fold excess of the unlabeled wild-type or mutant- 
type double-stranded KB oligonucleotide DNA and by DNA 
cross-linking experiments as reported previously [25,26,28] 
(data not shown). The specificity of the DNA-protein complex 
for NF-KB was also confirmed by the anti-NF-KB antibody 
that showed the supershift of the complex on EMSA (for 
examples see Figs. 2 and 3). 
3.2. Proteolytic effect of NF-KB by calpains on its DNA 
binding activity 
To examine the effects of NF-KB processing by calpains on 
DNA binding activity, NF-KB was first preincubated with 
calpain and EMSA was subsequently carried out using KB 
probe (Fig. 1). The DNA binding activity of NF-KB was 
abolished by preincubation with either type of calpain in a 
Ca’+-dependent fashion. Fig. 1 demonstrates that the aboli- 
tion of DNA binding activity of NF-KB is dose-dependent for 
both types of calpains (Fig. 1A) and Ca2+ ion (Fig. 1B). 
However, no effect was observed with either calpain or 
Ca2+ alone (Fig. IA, lanes 2, 7 and 8; Fig. IB, lanes 2 and 
6). As shown in Fig. lB, the proteolytic effect of m-calpain on 
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Fig. 1. Inhibition of DNA binding activity of NF-KB by calpains. 
The calpain-treated NF-rB samples were analyzed by electrophore- 
tic mobility shift assay (EMSA). (A) NF-KB was preincubated with 
p-calpain (lanes 3-6) or m-calpain (lanes 8-12) at the indicated con- 
centrations in the presence or absence of 1 mM Ca2+ at 30°C for 
60 min before adding the radiolabeled KB oligonucleotide probe. In 
lanes 2 and 8, NF-KB was preincubated with p-calpain or m-calpain 
without Ca’+. The closed triangle indicates the NF-KB-DNA com- 
plex. An asterisk indicates a non-specific band. (B) Effect of Ca2+ 
on the actions of p- or m-calpain. The NF-lcB and calpain were 
preincubated for 60 min at 30°C with different concentrations of 
Ca2+ as indicated before EMSA. 
the DNA binding activity of NF-KB appeared from as low a 
concentration as 1 mM of Ca’+. 
3.3. Effects of protease inhibitors on degradation of NF-KB by 
calpain 
In Figs. 2A and 3A, the time course of the action of cal- 
pains in blocking the DNA binding activity of NF-KB and the 
effects of protease inhibitors was examined. NF-KB was di- 
gested by p-calpain in the presence of calcium ion for 10, 30 
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and 60 min. After 10 and 30 min incubation of NF-KB with p- 
calpain, position of the DNA-protein complex was shifted 
downwards (Fig. 2A, lanes 2 and 3), suggesting the partial 
degradation of NF-KB by p-calpain. After incubation of 
NF-KB with p-calpain for 60 min, the DNA-protein complex 
disappeared completely. In contrast, incubation of NF-KB 
with m-calpain gradually blocked the NF-KB-DNA complex 
formation without affecting the mobility of the complex (Fig. 
3A). The disappearance of the NF-KB-DNA complex is con- 
A 
NF-KB + + + + 
Ca++ - + + + 
p-Calpain - + + + 
Reaction Time (min) 80’ lo’ 30’ 60 
B 
NF-KB 
Antl-NF-tcB(p65) 
ca++ 
p-Calpain 
Calpain inhibitor I 
Proteasome inhibitor 
Calpsstatin 
123456 
Fig. 2. Effect of p-calpain in the DNA binding activity of NF-KB. 
(A) Time course of NF-KB degradation with I-calpain (5 lg/ml, see 
section 2). Proteins were preincubated at 30°C for the indicated per- 
iods of time and subjected to EMSA. The closed triangle indicates 
the position of NF-KB-DNA complexes. The open triangle indicates 
the position of the NF-KB-DNA complexes after partial digestion 
with p-calpain. (B) Effects of protease inhibitors. 10 pM each of cal- 
pastatin domain I, proteasome inhibitor or calpain inhibitor I was 
preincubated with NF-KB in the presence of p-calpain and Ca*+ (1 
mM) for 30 min at 30°C before adding radiolabeled KB probe. An 
arrowhead from the right indicates the position of the supershifted 
band of the NF-KB-DNA complex. 
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1 2 3 4 5 6 
Fig. 3. Effect of m-calpain in the DNA binding activity of NF-KB. 
The experiments were similarly carried out as in Fig. 2 except that 
m-calpain was used. (A) Time course of NF-KB degradation with 
m-calpain (5 pg/ml, see section 2). NF-rB was preincubated with m- 
calpain in the presence of Ca*+ at 30°C for the indicated periods of 
time and subjected to EMSA. The closed triangle indicates the posi- 
tion of NF-KB-DNA complexes. In this series of experiments, the 
different preparation of NF-KB was utilized from that in Fig. 2. 
These bands were similarly retarded on a gel and supershifted by 
anti-p65 antibody as in Fig. 2 and were thus considered the same 
NF-KEGDNA complex. (B) Effects of protease inhibitors. 10 FM of 
calpastatin domain I, proteasome inhibitor or calpain inhibitor I 
was preincubated with NF-KB in the presence of m-calpain and 
CaZ+ (1 mM). An arrowhead from the right indicates the position 
of the supershifted band of the NF-KEDNA complex by anti-p65 
antibody. 
sidered to be due to proteolysis of NF-KB by calpains in the 
presence of calcium, although the modes of action appear to 
be different. 
We then examined the effects of protease inhibitors on this 
phenomenon with calpains. Calpastatin domain I, calpain in- 
hibitor I and proteasome inhibitor, which are known to be 
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Fig. 4. Western blot analysis of p65 processing by calpains. NF-KB 
was incubated with various concentrations of p-calpain (lanes 1-5) 
or m-calpain (lanes 7-11) at 30°C for 30 min in the presence of 
1 mM Ca’+. Positions of molecular weight markers (in kDa) are in- 
dicated on the left. 
effective inhibitors of p- and m-calpains [21,29,30], were added 
during the preincubation period of NF-KB with calpains to 
examine the specificity of proteolytic actions. The same molar 
concentration (10 PM) of either calpastatin domain I, protea- 
some inhibitor or calpain inhibitor I was added to the pre- 
incubation mixture containing p- or m-calpain and NF-KB for 
30 min at 30°C and EMSA was carried out (Figs. 2B and 3B, 
for p-calpain and m-calpain, respectively). The results showed 
that the abolition of NF-KB-DNA complex formation was 
most efficiently prevented by calpastatin, an endogenous cal- 
pain-specific inhibitor, although it was also prevented by the 
calpain inhibitor I and proteasome inhibitor to lesser extents. 
These observations confirmed that both types of calpains were 
responsible for the proteolysis of NF-KB and thus abolished 
NF-KB DNA binding activity. 
3.4. Western blot analysis of NF-KB processing b_v calpains 
We examined the proteolytic processing of NF-KB by p- or 
m-calpain using Western blot with the C-terminal peptide 
antibody to ~65. NF-KB was incubated with either p- or m- 
calpain in the presence of 1 mM Ca2+ at 30°C for 30 min. At 
CL-calpain and m-calpain concentrations higher than 3.2 and 
2.2 kg/ml, respectively, the specific p65 band disappeared (Fig. 
4). These observations confirmed that the abolition of the 
DNA binding of NF-KB activity is done by similar concentra- 
tions of both calpains. Since the degraded form of NF-KB was 
not detected by this C-terminal peptide antibody, both cal- 
pains were considered to cleave p65 at its C-terminal region. 
4. Discussion 
Most of the short-lived proteins contain one or more re- 
gions rich in proline (P), glutamic acid (E) and aspartic acid 
(D), serine (S) and threonine (T), which are known as ‘PEST’ 
regions [31]. Known PEST proteins include oncogene pro- 
ducts (c-Myc, c-Fos and c-Myb), enzymes (hydroxymethylglu- 
taryl-CoA reductase and ornithine decarboxylase) and com- 
ponents of signal pathways (kinases and steroid receptors) 
[311. 
These ‘PEST’ regions are considered to be recognized by a 
specific protease( 
Particularly, calpain is a candidate for the degradation of 
PEST-containing proteins [14,31]. By computer analysis of the 
amino acid sequences using PC Gene software (Intelligenetics, 
Mountain View, CA), three PEST regions (Pl: 279-294, P2: 
3 16-324, P3 : 5 10-551) were predicted in the p65 subunit of 
NF-KB but no typical PEST region was found in the p50 
subunit of NF-KB. The PEST scores of Pl to P3 were 5.81, 
3.39 and -0.81, respectively. Pl is located on the DNA bind- 
ing domain, P2 is adjacent to the DNA binding domain and 
P3 is located in the C-terminal end of ~65. 
We demonstrated in this paper that DNA binding activity 
of NF-KB was abolished by p- and m-calpain using EMSA 
(Fig. l-3). Using Western blotting assay, we demonstrated 
that p65 was actually cleaved by calpains at the similar effec- 
tive concentrations (Fig. 4). Degradation of NF-KB by calpain 
was efficiently inhibited by calpastatin domain I, proteasome 
inhibitor and calpain inhibitor I (Figs. 2 and 3). 
Since the anti-NF-KB (~65) C-terminal antibody did not 
detect the degraded forms of the p65 molecule (Fig. 4), it 
was suggested that calpains may degrade p65 at the C-term- 
inal region. p-Calpain may degrade p65 at the C-terminal 
region and at a region other than that involved in DNA 
binding since in the earlier step of protein processing we de- 
tected the lower molecular weight form of the protein-DNA 
complex (Fig. 2A). On the other hand, m-calpain may degrade 
p65 at the DNA binding domain as well as the C-terminal 
region since the NF-KB degraded by m-calpain immediately 
lost the DNA binding activity (Fig. 3A). These results are 
consistent with the notion of NF-KB as PEST-containing pro- 
teins and this report contributes one more example to the 
previous postulate that calpains recognize PEST proteins 
and regulate the steady-state level of a certain set of cellular 
proteins by proteolytic processing [ 18,311. 
Currently there are contradictory arguments with regard to 
the intracellular location of calpains [ 17,32-361. Although 
there have been a number of papers demonstrating that cal- 
pains are located mainly in the cytoplasm and very scarcely in 
the nucleus [32,33], recent papers have indicated the possibi- 
lity that m-calpain is located in the nucleus and involved in 
the processing of nuclear transcription factors [17,34-361. 
Furthermore, Onizuka et al. have recently demonstrated se- 
lective distribution of p-calpain in the nuclei of the central 
nervous system as well as peripheral nervous system neurons 
using specific anti-p-calpain antibody [37]. 
Considering the physiological role of Ca2+ mobilization 
upon stimulation of lymphocytes by various signals, our find- 
ings of the involvement of calcium-dependent proteases in the 
processing of the p65 subunit of NF-KB may have biological 
implications. Recent studies indicated that the C-terminal re- 
gion of p65 serves as a transcriptional activation domain 
[38,39]. The action of calpains upon the p65 molecule may 
have a regulatory role through specific proteolytic degrada- 
tion at this region and thus are considered to be involved in 
regulated expression of the target genes of NF-KB. Recogni- 
tion of a specific regulatory pathway in the processing of 
transcription factors such as shown here should provide a 
novel insight into gene regulation by transcription factors. 
Identification of effective protease inhibitors specific for the 
protein processing pathway would provide a novel strategy 
for disease control. 
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